{
    "title": "Revenue of Johnson & Johnson 's pharmaceuticals segment worldwide 2012 to 2024",
    "labels": [
        "Year",
        "Immunology",
        "Cardiovascular/Metabolism/Other",
        "Oncology",
        "Central nervous system",
        "Anti-infectives"
    ],
    "columnType": "multi",
    "graphType": "line",
    "summary": [
        "The statistic shows the Johnson Johnson Johnson & from 2024 to 2012 . ",
        "In 2019 , Johnson & in Immunology was the worldwide lowest at 11.69 % and rose to 7.87 % in 2012 . ",
        "As of that Year , Anti-infectives had the highest Johnson & among individuals with 3.19 % of the population accessing the Johnson ."
    ],
    "trends": [
        {
            "9": [
                "12",
                "0"
            ],
            "11": [
                "0",
                "0"
            ]
        },
        {
            "1": [
                "7",
                "0"
            ],
            "12": [
                "9",
                "1"
            ],
            "17": [
                "0",
                "1"
            ],
            "20": [
                "0",
                "0"
            ]
        },
        {
            "14": [
                "0",
                "5"
            ]
        }
    ],
    "data": [
        {
            "Year": "2012",
            "Immunology": "7.87",
            "Cardiovascular/Metabolism/Other": "4.94",
            "Oncology": "2.63",
            "Central nervous system": "6.72",
            "Anti-infectives": "3.19"
        },
        {
            "Year": "2013",
            "Immunology": "9.19",
            "Cardiovascular/Metabolism/Other": "4.95",
            "Oncology": "3.77",
            "Central nervous system": "6.67",
            "Anti-infectives": "3.55"
        },
        {
            "Year": "2014",
            "Immunology": "10.19",
            "Cardiovascular/Metabolism/Other": "5.58",
            "Oncology": "4.46",
            "Central nervous system": "6.49",
            "Anti-infectives": "5.6"
        },
        {
            "Year": "2015",
            "Immunology": "10.4",
            "Cardiovascular/Metabolism/Other": "6.42",
            "Oncology": "4.7",
            "Central nervous system": "6.26",
            "Anti-infectives": "3.66"
        },
        {
            "Year": "2016",
            "Immunology": "11.97",
            "Cardiovascular/Metabolism/Other": "6.4",
            "Oncology": "5.81",
            "Central nervous system": "6.08",
            "Anti-infectives": "3.21"
        },
        {
            "Year": "2017",
            "Immunology": "12.24",
            "Cardiovascular/Metabolism/Other": "6.29",
            "Oncology": "7.26",
            "Central nervous system": "5.99",
            "Anti-infectives": "3.15"
        },
        {
            "Year": "2018",
            "Immunology": "12.34",
            "Cardiovascular/Metabolism/Other": "7.19",
            "Oncology": "8.96",
            "Central nervous system": "5.74",
            "Anti-infectives": "3.18"
        },
        {
            "Year": "2019",
            "Immunology": "12.49",
            "Cardiovascular/Metabolism/Other": "7.27",
            "Oncology": "988.0",
            "Central nervous system": "4.93",
            "Anti-infectives": "3.79"
        },
        {
            "Year": "2020",
            "Immunology": "12.09",
            "Cardiovascular/Metabolism/Other": "7.1",
            "Oncology": "10.73",
            "Central nervous system": "4.84",
            "Anti-infectives": "3.95"
        },
        {
            "Year": "2021",
            "Immunology": "11.69",
            "Cardiovascular/Metabolism/Other": "7.09",
            "Oncology": "11.78",
            "Central nervous system": "4.94",
            "Anti-infectives": "4.38"
        },
        {
            "Year": "2022",
            "Immunology": "11.14",
            "Cardiovascular/Metabolism/Other": "6.93",
            "Oncology": "12.71",
            "Central nervous system": "5.05",
            "Anti-infectives": "5.02"
        },
        {
            "Year": "2023",
            "Immunology": "10.24",
            "Cardiovascular/Metabolism/Other": "6.8",
            "Oncology": "13.91",
            "Central nervous system": "4.68",
            "Anti-infectives": "5.45"
        },
        {
            "Year": "2024",
            "Immunology": "9.34",
            "Cardiovascular/Metabolism/Other": "6.79",
            "Oncology": "14.86",
            "Central nervous system": "5.03",
            "Anti-infectives": "5.94"
        }
    ],
    "gold": [
        "This statistic shows the revenue share of Johnson & Johnson 's pharmaceuticals segment worldwide from 2012 to 2024 , by product category. ",
        "Johnson & Johnson is a multi-national company , specialized on pharmaceuticals , medical devices and consumer goods. ",
        "The company is headquartered in New Brunswick , New Jersey ."
    ]
}